source
- Sanofi beats Q1 sales forecasts, driven by strong Dupixent demandSanofi reported first‑quarter results that exceeded Wall Street expectations, with net sales rising 6.2% to €10.5 billion (about $12.3 billion).\n\nThe growth was led by Dupixent, the anti‑inflamma…
- Trump touts completion of first round of White House drug pricing deals with RegeneronPresident Trump announced that a pricing agreement with Regeneron marks the final deal of an initial slate of 17 sought by the administration. Under the private arrangement, Regeneron will lower Me…